All In Biotech

Investigational drug · Phase 2

IAM1363

Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for HER2 Mutation-Related Tumors, HER2, HER2-positive Breast Cancer.

Phase 2

Last checked: Nov 19, 2026Latest source record: Nov 17, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 2

Industry-sponsored trials

Phase 2 and 3 trials

1

1 still active

All registered trials

1

Any phase or sponsor naming "IAM1363"

First trial start

2024

Mar 25, 2024

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "IAM1363", any sponsor or status.

Conditions studied

As listed on its trial records.

  • HER2 Mutation-Related Tumors
  • HER2
  • HER2-positive Breast Cancer
  • HER2 + Breast Cancer
  • Brain Metastases From Solid Tumors
  • Brain Metastases From HER2 and Breast Cancer
  • CNS Metastases
  • HER2-Positive Solid Tumors
  • NSCLC (Non-small Cell Lung Cancer)
  • HER2-positive Bladder Cancer

Approved drugs for the same conditions: Breast cancer · Non-small cell lung cancer · Small cell lung cancer · Bladder and urothelial cancer · Oncology · Kidney and urology

Largest trials

Live from ClinicalTrials.gov: studies naming "IAM1363" as an intervention, largest first.

All trials
  • Iambic Therapeutics, IncIndustry

    NCT06253871 · 463 participants (planned) · Start Mar 25, 2024 · Primary completion Oct 2028

    Drug: IAM1363; Oral treatment with IAM1363 capsules or tablets, administered in combination with capecitabine + trastuzumab and 3 more · For: HER2 Mutation-Related Tumors; HER2; HER2-positive Breast Cancer and 10 more

    Sites: La Jolla, California; Los Angeles, California; Aurora, Colorado · 53 sites in all

Newest research

PubMed records naming it or its code names, newest first.

All 0 on PubMed

No PubMed records name it yet, which is common for early code-named drugs.

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.